En Es
Categories

Industry News


Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership

By Labmedica International staff writers
28 Oct 2020

Image: Vivalytic SARS-CoV-2 rapid test (Photo courtesy of Randox Laboratories)The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory settings for rapidly detecting COVID-19.

Providing clear and concise results, direct at the point of care, the collaborative approach of Randox and Bosch Healthcare not only allows patients to take the recommended safety precautions without delay, but also provides solutions to both analyze and differentiate COVID-19 from other viral respiratory diseases. Their combined efforts have resulted in the launch of the Vivlaytic, an all in one solution for molecular diagnostics consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection in one small platform. These efforts reflect the global partnership between the companies who are working together to deliver world-class diagnostic solutions, harnessing the power of innovation to improve health worldwide, and providing an all-in-one approach for minimizing the spread of COVID-19 globally.

The Viral Respiratory Infection array (VRI) rapidly detects the SARS-CoV-2 virus that causes COVID-19 while simultaneously differentiating between nine other respiratory diseases, in less than two and a half hours. Randox, Bosch Healthcare and R-Biopharm also offer various analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among the fastest PCR tests worldwide.

Randox and Bosch Healthcare offer a range of different testing strategies, including the upcoming SARS-CoV-2 Pooling test. The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentralized testing approach for effectively and efficiently monitoring and detecting viral infection from the onset. The solution is capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously with a capacity for processing more than 160 patient samples a day. Sample pooling allows more people to be tested quickly using fewer testing resources. The pooling can be done at the level of a ward, medical specialty, social bubble, or a group of colleagues. It also has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces.




E-mail Print
FaceBook Twitter Google+ Linked in

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmaceutical companies and veterinary clinics, including clinical chemistry and immunoassay analysers, high quality reagents, and quality control material.
Gold member
More info

More articles about Randox Laboratories

01 Mar 2018
Randox and Bosch Partner to Launch Molecular Diagnostics Platform
Global healthcare diagnostics manufacturer Randox Laboratories has partnered with Bosch Healthcare Solutions GmbH to launch Vivalytic, an all-in-one fully automated solution for molecular diagnostics.
Read More

Additional news

26 Jul 2021
GE Healthcare Backs Development of Innovative Total-Body PET/CT Scanner for Simultaneous Whole-Body Imaging
GE Healthcare (Chicago, IL, USA) is backing a collaboration among Quibim (Valenciana, Spain), Full Body Insight, and Oncovision (Valenciana, Spain) to build an innovative total-body PET/CT scanner for simultaneous whole-body imaging.
Read More
23 Jul 2021
RSNA 2021 to Be In-Person Event with Demonstrations of Latest Medical Imaging Technologies in CT, MRI and AI
The world's largest radiology forum is all set to offer robust in-person scientific assembly and technical exhibition with demonstrations of the latest medical imaging technologies in CT, MRI, artificial intelligence (AI), 3D printing and more.
Read More
21 Jul 2021
BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.
Read More
19 Jul 2021
ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC
ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders.
Read More
16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More
14 Jul 2021
Global Smart Hospitals Market to Reach USD 221.3 Billion by 2030 Due to Proliferation of ML, AI and IoT
The global smart hospitals market is expected to reach USD 221.3 billion by the end of 2030 due to health professionals increasing their usage of electronic health records and connected medical assistance.
Read More
13 Jul 2021
AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.
Read More
13 Jul 2021
Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.
Read More
08 Jul 2021
Global AI-Based Surgical Robots Market to Reach USD 17.2 Billion by 2028
The global AI-based surgical robots market size is expected to expand at a CAGR of 17.2% from 2021 to 2028 to reach USD 17.2 billion by 2028, driven by increased efficiency and success rate offered by robotic surgeries, along with a shift in the preference for minimally invasive surgeries by patients over traditional methods.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions